Antiviral phosphonate analogs

Abstract

The invention is related to phosphorus substituted compounds with antiviral activity, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

1 . A conjugate of the following formula: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt or solvate thereof; 
       
       wherein:
 B is selected from adenine, guanine, cytosine, uracil, thymine, 7-deazaadenine, 7-deazaguanine, 7-deaza-8-azaguanine, 7-deaza-8-azaadenine, inosine, nebularine, nitropyrrole, nitroindole, 2-aminopurine, 2-amino-6-chloropurine, 2,6-diaminopurine, hypoxanthine, pseudouridine, pseudocytosine, pseudoisocytosine, 5-propynylcytosine, isocytosine, isoguanine, 7-deazaguanine, 2-thiopyrimidine, 6-thioguanine, 4-thiothymine, 4-thiouracil, O 6 -methylguanine, N 6 -methyladenine, O 4 -methylthymine, 5,6-dihydrothymine, 5,6-dihydrouracil, 4-methylindole, substituted triazole, and pyrazolo[3,4-d]pyrimidine; 
 X is selected from O, C(R y ) 2 , OC(R y ) 2 , NR and S; 
 Z is independently selected from H, OH, OR, NR 2 , CN, NO 2 , SH, SR, F, Cl, Br, and I; 
 Y 1  is independently O, S, NR,  + N(O)(R), N(OR),  + N(O)(OR), or N—NR 2 ; 
 Y 2  of the moiety 
 
       
         
           
           
               
               
           
         
       
       is independently CR 2 , NR,  + N(O)(R), N(OR),  + N(O)(OR), N—NR 2 , S, S—S, S(O), or S(O) 2 ;
 Y 2  of the moiety 
 
       
         
           
           
               
               
           
         
       
       is independently O, CR 2 , NR,  + N(O)(R), N(OR),  + N(O)(OR), N—NR 2 , S, S—S, S(O), or S(O) 2 ;
 M2 is 0, 1 or 2; 
 R y  is independently H, F, Cl, Br, I, OH, —C(═Y 1 )R, —C(═Y 1 )OR, —C(═Y 1 )N(R) 2 , —N(R) 2 , — + N(R) 3 , —SR, —S(O)R, —S(O) 2 R, —S(O)(OR), —S(O) 2 (OR), —OC(═Y 1 )R, —OC(═Y 1 )OR, —OC(═Y 1 )(N(R) 2 ), —SC(═Y 1 )R, —SC(═Y 1 )OR, —SC(═Y 1 )(N(R) 2 ), —N(R)C(═Y 1 )R, —N(R)C(═Y 1 )OR, or —N(R)C(═Y 1 )N(R) 2 , amino (—NH 2 ), ammonium (—NH 3   + ), alkylamino, dialkylamino, trialkylammonium, C 1 -C 8  alkyl, C 1 -C 8  alkylhalide, carboxylate, sulfate, sulfamate, sulfonate, 5-7 membered ring sultam, C 1 -C 8  alkylsulfonate, C 1 -C 8  alkylamino, 4-dialkylaminopyridinium, C 1 -C 8  alkylhydroxyl, C 1 -C 8  alkylthiol, alkylsulfone (—SO 2 R), arylsulfone (—SO 2 Ar), arylsulfoxide (—SOAr), arylthio (—SAr), sulfonamide (—SO 2 NR 2 ), alkylsulfoxide (—SOR), ester (—C(═O)OR), amido (—C(═O)NR 2 ), 5-7 membered ring lactam, 5-7 membered ring lactone, nitrile (—CN), azido (—N 3 ), nitro (—NO 2 ), C 1 -C 8  alkoxy (—OR), C 1 -C 8  alkyl, C 1 -C 8  substituted alkyl, C 1 -C 8  alkenyl, C 1 -C 8  substituted alkenyl, C 1 -C 8  alkynyl, C 1 -C 8  substituted alkynyl, C 6 -C 20  aryl, C 6 -C 20  substituted aryl, C 2 -C 20  heterocycle, C 2 -C 20  substituted heterocycle, polyethyleneoxy, or W 3 ; or when taken together, R y  forms a carbocyclic ring of 3 to 7 carbon atoms; 
 R x  is independently R y , a protecting group, or the formula: 
 
       
         
           
           
               
               
           
         
         wherein: 
         M1a, M1c, and M1d are independently 0 or 1; 
         M12c is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12; and 
         R is C 1 -C 8  alkyl, C 1 -C 8  substituted alkyl, C 1 -C 8  alkenyl, C 1 -C 8  substituted alkenyl, C 1 -C 8  alkynyl, C 1 -C 8  substituted alkynyl, C 6 -C 20  aryl, C 6 -C 20  substituted aryl, C 2 -C 20  heterocycle, C 2 -C 20  substituted heterocycle, or a protecting group; and 
         W 3  is W 4  or W 5 , where W 4  is R, —C(Y 1 )R y , —C(Y 1 )W 5 , —SO 2 R y , or —SO 2 W 5 ; and W 5  is a carbocycle or a heterocycle wherein W 5  is independently substituted with 0 to 3 R y  groups. 
       
     
     
         2 . The conjugate of  claim 1  wherein C 1 -C 8  substituted alkyl, C 1 -C 8  substituted alkenyl, C 1 -C 8  substituted alkynyl, C 6 -C 20  substituted aryl, and C 2 -C 20  substituted heterocycle are independently substituted with one or more substituents selected from F, Cl, Br, I, OH, —NH 2 , —NH 3   + , —NHR, —NR 2 , —NR 3   + , C 1 -C 8  alkylhalide, carboxylate, sulfate, sulfamate, sulfonate, 5-7 membered ring sultam, C 1 -C 8  alkylsulfonate, C 1 -C 8  alkylamino, 4-dialkylaminopyridinium, C 1 -C 8  alkylhydroxyl, C 1 -C 8  alkylthiol, —SO 2 R, —SO 2 Ar, —SOAr, —SAr, —SO 2 NR 2 , —SOR, —CO 2 R, —C(═O)NR 2 , 5-7 membered ring lactam, 5-7 membered ring lactone, —CN, —N 3 , —NO 2 , C 1 -C 8  alkoxy, C 1 -C 8  trifluoroalkyl, C 1 -C 8  alkyl, C 3 -C 12  carbocycle, C 6 -C 20  aryl, C 2 -C 20  heterocycle, polyethyleneoxy, phosphonate, phosphate, and a prodrug moiety. 
     
     
         3 . The conjugate of  claim 1  wherein protecting group is selected from a carboxyl ester, a carboxamide, an aryl ether, an alkyl ether, a trialkylsilyl ether, a sulfonic acid ester, a carbonate, and a carbamate. 
     
     
         4 . The conjugate of  claim 1  wherein W 5  is selected from the structures: 
       
         
           
           
               
               
           
         
       
     
     
         5 . The conjugate of  claim 1  wherein X is O and each R y  is H. 
     
     
         6 . The conjugate of  claim 1  wherein the conjugate is a resolved enantiomer having the structure: 
       
         
           
           
               
               
           
         
       
     
     
         7 . The conjugate of  claim 1  wherein the conjugate is a resolved enantiomer having the structure: 
       
         
           
           
               
               
           
         
       
     
     
         8 . The conjugate of  claim 1  having the structure: 
       
         
           
           
               
               
           
         
       
     
     
         9 . The conjugate of  claim 1  having the structure: 
       
         
           
           
               
               
           
         
       
     
     
         10 . The conjugate of  claim 1  having the structure: 
       
         
           
           
               
               
           
         
       
     
     
         11 . The conjugate of  claim 1  having the structure: 
       
         
           
           
               
               
           
         
       
     
     
         12 . The conjugate of  claim 1  having the structure: 
       
         
           
           
               
               
           
         
       
       wherein R 2  is H or C 1 -C 8  alkyl. 
     
     
         13 . The conjugate of  claim 1  having the structure: 
       
         
           
           
               
               
           
         
       
     
     
         14 . The conjugate of  claim 13  wherein Z is H. 
     
     
         15 . The conjugate of  claim 13  wherein B is adenine. 
     
     
         16 . The conjugate of  claim 13  having the structure: 
       
         
           
           
               
               
           
         
       
       wherein Y 2c  is O, N(R y ) or S. 
     
     
         17 . The conjugate of  claim 16  having the structure: 
       
         
           
           
               
               
           
         
       
     
     
         18 . The conjugate of  claim 17  wherein Y 2c  is O. 
     
     
         19 . The conjugate of  claim 17  wherein Y 2c  is N(CH 3 ). 
     
     
         20 . The conjugate of  claim 1  wherein substituted triazole has the structure: 
       
         
           
           
               
               
           
         
       
     
     
         21 . A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a conjugate as described in  claim 1 , or a pharmaceutically acceptable salt or solvate thereof. 
     
     
         22 . A method for promoting an anti-viral effect in vitro or in vivo comprising contacting a sample in need of such treatment with a a conjugate as described in  claim 1 , or a pharmaceutically acceptable salt or solvate thereof. 
     
     
         23 . A method of inhibiting a viral infection in an animal, comprising administering an effective amount of a conjugate as described in  claim 1 , or a pharmaceutically acceptable salt or solvate thereof, to the animal.